Clinical EvaluatioN of TElmisartan-Based Antihypertensive Regimen

This study has been completed.

First Received: January 31, 2008 Last Updated: January 30, 2009 History of Changes

Sponsor:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00613314

Purpose

To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.

Condition
Hypertension Metabolic Syndrome X

Study Type:	Observational
Official Title:	Clinical EvaluatioN of TElmisartan-Based Antihypertensive Regimen (CENTER)

Resource links provided by NLM:

MedlinePlus related topics: Blood Pressure Medicines High Blood Pressure Metabolic Syndrome

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Enrollment:	14478
Study Start Date:	June 2007
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	45 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age > 45 years increased waist circumference (>88.9cm [>35in] men, >78.7cm [>31in] for women) elevated triglycerides (>150mg/dl) low HDL cholesterol (<40mg/dl in men, <50mg/dl in women) hypertension (>130/>85mmHG) impaired fasting glucose (>110mg/dl) (8) hypertensive patient assessed to benefit from telmisartan based treatment

Exclusion Criteria:

hypersensitivity to telmisartan, HCTZ and its excipients <3 months MI, stroke or severe heart failure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00613314

Show 126 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	502.532
Study First Received:	January 31, 2008
Last Updated:	January 30, 2009
ClinicalTrials.gov Identifier:	NCT00613314 History of Changes
Health Authority:	Philippines: Department of Health Bureau of Food and Drugs

Additional relevant MeSH terms:

Metabolic Syndrome X
Disease
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Protease Inhibitors
Angiotensin II Type 1 Receptor Blockers

Hyperinsulinism
Pathologic Processes
Therapeutic Uses
Syndrome
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Insulin Resistance
Telmisartan
Glucose Metabolism Disorders
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010